Strategy for the Quantitation of a Protein Conjugate via Hybrid Immunocapture-Liquid Chromatography with Sequential HRMS and SRM-Based LC-MS/MS Analyses.

With the development of modern instrumentation and technologies, mass spectrometry based assays have played an important role in protein bioanalysis. We have developed a novel strategy by combining the "bottom-up" and "top-down" approaches using both high-resolution (HRMS) and selected reaction monitoring (SRM) based mass spectrometric detection to quantify a positron emission tomography (PET) detection tracer for an oncology marker. Monkey plasma samples were processed by immunocapture purification, followed by liquid chromatography (LC) with HRMS full scan analysis. Summed multiple charge states and multiple isotopes per charge state of the analyte were used during quantitation for optimized sensitivity. After the HRMS analysis, the remaining samples were digested by trypsin, followed by SRM detection. The HRMS approach provided the solution to a unique problem related to stability of the protein conjugate by quantifying the intact protein. The SRM method only measured a signature peptide generated from enzymatic digestion, but had a lower quantitation limit to meet the sensitivity requirement to assess the pharmacokinetics in a toxicology study. Both methods demonstrated good sensitivity, accuracy, precision and robustness, and the results revealed that there was no significant difference between the data sets obtained from both methods, indicating no in vivo or ex vivo degradation occurred in the incurred samples after dosing. This workflow not only provided the quantitative results for pharmacokinetic evaluation, but also revealed valuable in vivo stability information on the intact protein level.

[1]  Jim X. Shen,et al.  A novel and cost effective method of removing excess albumin from plasma/serum samples and its impacts on LC-MS/MS bioanalysis of therapeutic proteins. , 2014, Analytical chemistry.

[2]  W. Shou,et al.  Simple means to alleviate sensitivity loss by trifluoroacetic acid (TFA) mobile phases in the hydrophilic interaction chromatography-electrospray tandem mass spectrometric (HILIC-ESI/MS/MS) bioanalysis of basic compounds. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[3]  R. Bischoff,et al.  High-sensitivity LC-MS/MS quantification of peptides and proteins in complex biological samples: the impact of enzymatic digestion and internal standard selection on method performance. , 2013, Analytical chemistry.

[4]  L. Burton,et al.  A workflow for absolute quantitation of large therapeutic proteins in biological samples at intact level using LC-HRMS. , 2016, Bioanalysis.

[5]  Zheng Ouyang,et al.  A universal surrogate peptide to enable LC-MS/MS bioanalysis of a diversity of human monoclonal antibody and human Fc-fusion protein drug candidates in pre-clinical animal studies. , 2012, Biomedical chromatography : BMC.

[6]  Jim X. Shen,et al.  Orthogonal extraction/chromatography and UPLC, two powerful new techniques for bioanalytical quantitation of desloratadine and 3-hydroxydesloratadine at 25 pg/mL. , 2006, Journal of pharmaceutical and biomedical analysis.

[7]  W. Humphreys,et al.  Strategy and its implications of protein bioanalysis utilizing high-resolution mass spectrometric detection of intact protein. , 2011, Analytical chemistry.

[8]  I. Broek,et al.  LC-MS-based quantification of intact proteins: perspective for clinical and bioanalytical applications. , 2015 .

[9]  Darrell Ricke,et al.  Absolute quantification of monoclonal antibodies in biofluids by liquid chromatography-tandem mass spectrometry. , 2008, Analytical chemistry.

[10]  Christopher Singleton,et al.  Recent advances in bioanalytical sample preparation for LC-MS analysis. , 2012, Bioanalysis.

[11]  T. Olah,et al.  Application and challenges in using LC-MS assays for absolute quantitative analysis of therapeutic proteins in drug discovery. , 2014, Bioanalysis.

[12]  Qin C Ji,et al.  Liquid chromatography coupled with tandem mass spectrometry for the bioanalysis of proteins in drug development: practical considerations in assay development and validation. , 2013, Journal of chromatography. A.

[13]  Jim X. Shen,et al.  Using temperature to optimize resolution and reduce analysis times for bioanalytical diastereomer LC-MS/MS separations. , 2011, Journal of pharmaceutical and biomedical analysis.

[14]  M. Macht Mass spectrometric top-down analysis of proteins. , 2009, Bioanalysis.

[15]  Davide Verotta,et al.  Pharmacokinetic–Pharmacodynamic Modelling: History and Perspectives , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[16]  Jim X. Shen,et al.  Stereoselective quantitation of a serine protease inhibitor using LC-MS/MS at elevated column temperature. , 2008, Journal of separation science.

[17]  U. Mahmood,et al.  Pharmacodynamic Imaging Guides Dosing of a Selective Estrogen Receptor Degrader , 2015, Clinical Cancer Research.

[18]  David A. Mankoff,et al.  Quantitative Imaging of Estrogen Receptor Expression in Breast Cancer with PET and 18F-Fluoroestradiol , 2008, Journal of Nuclear Medicine.

[19]  Irene van den Broek,et al.  Bioanalytical LC-MS/MS of protein-based biopharmaceuticals. , 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[20]  William S. Hancock,et al.  Development of different analysis platforms with LC-MS for pharmacokinetic studies of protein drugs. , 2009, Analytical chemistry.

[21]  J. Wagner,et al.  History of pharmacokinetics. , 1981, Pharmacology & therapeutics.

[22]  Jim X. Shen,et al.  Development and validation of a liquid chromatography tandem mass spectrometry assay for the quantitation of a protein therapeutic in cynomolgus monkey serum. , 2015, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[23]  Todd Hager,et al.  Differential enzyme-linked immunosorbent assay and ligand-binding mass spectrometry for analysis of biotransformation of protein therapeutics: application to various FGF21 modalities. , 2013, Analytical chemistry.

[24]  Anne-Françoise Aubry,et al.  LC-MS/MS bioanalytical challenge: ultra-high sensitivity assays. , 2011, Bioanalysis.

[25]  Jim X. Shen,et al.  Strategies for improving sensitivity and selectivity for the quantitation of biotherapeutics in biological matrix using LC-MS/MS , 2015, Expert review of proteomics.

[26]  J. Prell,et al.  Protein Conformation and Supercharging with DMSO from Aqueous Solution , 2011, Journal of the American Society for Mass Spectrometry.

[27]  Yutaka Fujisawa,et al.  Differentiation of malignant tumours from granulomas by using dynamic [18F]-fluoro-L-α-methyltyrosine positron emission tomography , 2015, EJNMMI Research.

[28]  Pier Giorgio Righetti,et al.  Bioanalysis: Its past, present, and some future , 2004, Electrophoresis.

[29]  P. Choyke,et al.  Utility of 18F-fluoroestradiol (18F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[30]  Andrew N Hoofnagle,et al.  Replacing immunoassays with tryptic digestion-peptide immunoaffinity enrichment and LC-MS/MS. , 2012, Bioanalysis.

[31]  T. Olah,et al.  Quantitation of therapeutic proteins following direct trypsin digestion of dried blood spot samples and detection by LC-MS-based bioanalytical methods in drug discovery. , 2012, Bioanalysis.

[32]  Leimin Fan,et al.  Recent advances in high-throughput quantitative bioanalysis by LC-MS/MS. , 2007, Journal of pharmaceutical and biomedical analysis.

[33]  Neil L. Kelleher,et al.  Applying Label-Free Quantitation to Top Down Proteomics , 2014, Analytical chemistry.